Literature DB >> 2914942

A single base mutation that converts glycine 907 of the alpha 2(I) chain of type I procollagen to aspartate in a lethal variant of osteogenesis imperfecta. The single amino acid substitution near the carboxyl terminus destabilizes the whole triple helix.

C T Baldwin1, C D Constantinou, K W Dumars, D J Prockop.   

Abstract

Type I procollagen was examined in cultured skin fibroblasts from a patient with a lethal variant of osteogenesis imperfecta. About half of the pro-alpha chains were post-translationally overmodified and had a decreased thermal stability. The vertebrate collagenase A fragment had a normal thermal stability, but the B fragment had a decreased thermal stability. Therefore, there was a change in primary structure in amino acids 776-1014 of either the alpha 1(I) or alpha 2(I) chain. Three of five cDNA clones for the alpha 2(I) chain contained a single-base substitution of an A for a G that converted the codon for glycine at amino acid position 907 to aspartate. Complete nucleotide sequencing of bases coding for amino acids 776 to 1014 of the alpha 2(I) chain was carried out in one cDNA clone that contained the mutation in the glycine codon and in one that did not. Also, nucleotide sequencing was performed of bases coding for amino acids 776-1014 of the alpha 1(I) chain in seven independent cDNA clones. No other mutations were found. Therefore, the single base substitution that converts glycine 907 in the alpha 2(I) chain to aspartate is solely responsible for the decreased thermal stability of the type I procollagen synthesized by the proband's fibroblasts. Also, glycine 907 of the alpha 2(I) chain is an important component of a cooperative block that determines the melting temperature of the whole molecule.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2914942

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Osteogenesis imperfecta: translation of mutation to phenotype.

Authors:  P H Byers; G A Wallis; M C Willing
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

Review 2.  The triple helix of collagens - an ancient protein structure that enabled animal multicellularity and tissue evolution.

Authors:  Aaron L Fidler; Sergei P Boudko; Antonis Rokas; Billy G Hudson
Journal:  J Cell Sci       Date:  2018-04-09       Impact factor: 5.285

3.  Characterization of a type I collagen alpha 2(I) glycine-586 to valine substitution in osteogenesis imperfecta type IV. Detection of the mutation and prenatal diagnosis by a chemical cleavage method.

Authors:  J F Bateman; M Hannagan; D Chan; W G Cole
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

4.  Inductive Effects on the Energetics of Prolyl Peptide Bond Isomerization: Implications for Collagen Folding and Stability.

Authors:  Eric S Eberhardt; Nicholas Panisik; Ronald T Raines
Journal:  J Am Chem Soc       Date:  1996       Impact factor: 15.419

5.  Distinct biochemical phenotypes predict clinical severity in nonlethal variants of osteogenesis imperfecta.

Authors:  R J Wenstrup; M C Willing; B J Starman; P H Byers
Journal:  Am J Hum Genet       Date:  1990-05       Impact factor: 11.025

6.  Substitution of cysteine for glycine at residue 415 of one allele of the alpha 1(I) chain of type I procollagen in type III/IV osteogenesis imperfecta.

Authors:  A C Nicholls; J Oliver; D V Renouf; M Keston; F M Pope
Journal:  J Med Genet       Date:  1991-11       Impact factor: 6.318

7.  Dominant mutations in familial lethal and severe osteogenesis imperfecta.

Authors:  L Cohen-Solal; J Bonaventure; P Maroteaux
Journal:  Hum Genet       Date:  1991-07       Impact factor: 4.132

8.  Structure of cDNA clones coding for the entire prepro alpha 1 (III) chain of human type III procollagen. Differences in protein structure from type I procollagen and conservation of codon preferences.

Authors:  L Ala-Kokko; S Kontusaari; C T Baldwin; H Kuivaniemi; D J Prockop
Journal:  Biochem J       Date:  1989-06-01       Impact factor: 3.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.